Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. - Wikidata - awgldk - TriplyDB

Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.

Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.

http://www.wikidata.org/entity/Q34177643

about

Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects Mirtazapine inhibits tumor growth via immune response and serotonergic system Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development LSD-induced entropic brain activity predicts subsequent personality change.Postnatal serotonin type 2 receptor blockade prevents the emergence of anxiety behavior, dysregulated stress-induced immediate early gene responses, and specific transcriptional changes that arise following early life stress.Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors--a new analysis of data from the archives and implications for improved antimanic treatments.Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity.Enhanced function of prefrontal serotonin 5-HT(2) receptors in a rat model of psychiatric vulnerability.Rediscovering trazodone for the treatment of major depressive disorder Aporphinoid antagonists of 5-HT2A receptors: further evaluation of ring A substituents and the size of ring C.The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine.ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus.Platelet serotonergic markers as endophenotypes for obsessive-compulsive disorder.A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation.The role of serotonin receptor subtypes in treating depression: a review of animal studies A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder.Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex.A review of antipsychotics in the treatment of obsessive compulsive disorder.Candidate genes for antidepressant response to selective serotonin reuptake inhibitors Regulation of rat cortical 5-hydroxytryptamine2A receptor-mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine.Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses.Comparison of female Fischer and Sprague-Dawley rats in the response to ketanserin.Mechanism of action of trazodone: a multifunctional drug.Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission Augmentation strategies in obsessive-compulsive disorder.Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication.Looking back (and in)to the future: A personal reflection on 'Serotonin autoreceptor function and antidepressant drug action' (Hjorth et al., 2000).Increased levels of 5HT2A receptor mRNA expression in peripheral blood mononuclear cells of patients with major depression: correlations with severity and duration of illness.5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic study Atypical antipsychotics and inverse agonism at 5-HT2 receptors.Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects.Serotonin shapes risky decision making in monkeys.Cortical 5-hydroxytryptamine2A-receptor mediated excitatory synaptic currents in the rat following repeated daily fluoxetine administration.

P2860

Q23913111-9945E817-87F5-4174-B4FC-A01941F4A0B3 Q24243827-22F75928-17D8-4590-87C0-B0E43487CF89 Q24595389-1249B96B-2D33-473C-A93B-124385DD0AF2 Q26752771-2D9DE909-0095-4148-8CE0-49F0B0B7D8E4 Q28307374-23E0B0C8-5611-4933-A85E-7DDA293EC502 Q28481311-FCAB220C-7BED-44F2-8930-04F66466F7C3 Q28741999-D85A93DA-CF38-45C7-83C4-C2EE6E80724E Q30387757-0A6B7463-D2E9-4413-97FD-D2235E05CA05 Q30471963-D6111575-A0A7-4E41-80C5-B686C1CF4AED Q31163228-67CA8EB5-F98B-4191-9506-577BD4220F09 Q33616439-F9E51A5F-3FD3-4645-BF80-FDC33877F393 Q34253463-A5E13593-4088-4781-A488-E68ABD6B68B9 Q34314280-1283C230-A259-42EB-B641-738E2592E14E Q34339077-2FA1579F-770F-4F5D-A09A-1D14E217B367 Q34340909-666E281B-D1E0-41CA-B31D-18E679062A88 Q34417806-79C47B8B-F514-4D15-9C00-64449482F5C2 Q34470362-4F496F6A-B100-4271-BAB8-BA50DAEFCB03 Q34660430-7A5E3F60-2053-49DC-AA58-5A5B0F86081B Q35828514-7B7CB61C-55E2-4A4F-840A-6BC35E99B0D2 Q35936259-4EB0D118-0E8F-4900-B4AE-450509F11A37 Q36031101-0FF468AF-F61A-4CF5-A438-5FF69CE2C6EC Q36062173-7529FD0D-4995-4AD7-BC6B-C2439AAAABE4 Q36082843-DDAF9E0B-C166-47AB-AFEA-C81C7D4F4813 Q36137345-36D4ADAF-1F30-40F4-AF43-DF70491979BB Q36276544-F01EB451-D020-4746-B30C-5B6BC228645B Q36718053-DFD663AD-F6D2-41E2-A405-34D238C1907F Q36755908-20F0B860-989F-4808-AE06-C0B26B06E6D8 Q37288785-2C288EC4-39CC-4F46-BCFD-7FCB6D9C75F5 Q37515934-F58A9EAC-412F-446A-842E-734A1B54C808 Q37679880-433DDA99-FE1B-4390-867D-A8FED2209329 Q37949586-753877C3-E091-4F8D-8D33-4695E345DF45 Q38078029-C1E87D6C-D73B-4BA5-9026-771EC9A7FD10 Q38122158-0F3CEA1C-DB39-4F76-8621-C9D8E95C6551 Q38868838-4A5F8788-B4B0-46AA-9B69-A70B6956FD71 Q38997609-99101036-3E5F-459D-A9FA-09BFE7B28BF0 Q40698477-13816C66-83C7-4C42-90D1-A1792AC59F7B Q41250110-7812D80C-FFAF-47B0-9265-58AE5BB5EE9F Q41881371-486D0B85-9405-4B51-98C2-4B5295CFE939 Q41948817-74100118-DB9A-40E1-9C80-BCF69FFA2C2B Q42434631-329FEAB0-03EF-4A00-873E-5881A5F66D84

P2860

Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.

http://www.wikidata.org/entity/Q34177643

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@ast

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@en

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@nl

type

label

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@ast

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@en

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@nl

prefLabel

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@ast

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@en

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@nl

P1433

Q34177643-CD59D697-FF9A-4D63-8550-E78F95F057A4

P1476

Q34177643-97F71221-7462-4E0F-BDFA-742B5A0E1F4D

P2093

Q34177643-1C4BD332-D8CC-4712-BC31-B5C61C5758C3

Q34177643-3E0098D1-F427-486D-BECE-9F3221D78FE5

Q34177643-49D97D57-88E2-4B03-8153-AE45BFBAA526

Q34177643-72D641A4-13E6-40E9-BA72-609F15D05DFB

P2860

Q34177643-02BDBBED-A965-4459-9A23-3C7344F74379

Q34177643-110C74D4-10F8-4AFA-912A-223A4AA0F512

Q34177643-2168F193-3D97-4D83-BF3A-853E9DF2E333

Q34177643-21AA17C8-D774-486A-8197-F678DAB13EF3

Q34177643-22D95953-E3DF-4D0A-A5C9-A5347688F246

Q34177643-2B9B6E45-0DC9-4EE3-9FE6-B56D0A771A88

Q34177643-2E092CC3-207A-43E8-9DBE-24AC77C2B431

Q34177643-30C57270-FF43-4AE4-B8EF-FD1E1048DE54

Q34177643-313B02D7-3420-4395-B3D1-BAEE468908C3

Q34177643-33A5B930-4A6E-4D03-AF44-FD0888C0841E

P2888

Q34177643-BA86F6E5-F17D-4838-8815-A666AA65609F

P304

Q34177643-84822D73-5758-45D0-8E74-85C049966314

P31

Q34177643-D4F788C6-2C6D-4374-9C7C-3C0535333DA0

P356

Q34177643-A3C169F4-0582-4E8B-83C6-CD44ACE4F948

P407

Q34177643-BCF04B8F-D9F0-42ED-AAEA-AB7E1440D6FD

P433

Q34177643-F7B9007A-8D82-4A21-8A06-D3D3680857CA

P478

Q34177643-5CA5954C-4C69-42CF-A9E0-B417D507220A

P577

Q34177643-395F9A58-85DE-42EC-91F3-4DF92D86BEDF

P5875

Q34177643-667CD5F8-ABBD-4EDD-8243-2590946B70A8

P6179

Q34177643-28ACB72F-0C38-4A46-9FD3-B435287DF9FF

P698

Q34177643-CD7389E2-5616-4EDC-8BD9-393A318C1E18

P921

Q34177643-b7284c2f-cacf-4706-9ac0-6c0cd590a041

P356

P1433

Neuropsychopharmacology

P1476

Synergistic action of 5-HT2A a ...... in neuropsychiatric disorders.

@en

P2093

Christopher J McDougle

http://www.w3.org/2001/XMLSchema#string

Gerard J Marek

http://www.w3.org/2001/XMLSchema#string

Lawrence H Price

http://www.w3.org/2001/XMLSchema#string

Linda L Carpenter

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate

The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells.

Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release

Olanzapine and obsessive-compulsive symptoms

Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex

The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus

RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

P2888

P304

402-412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1300057

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10898682

http://www.w3.org/2001/XMLSchema#string

P6179

1026504371

http://www.w3.org/2001/XMLSchema#string

P698

12589395

http://www.w3.org/2001/XMLSchema#string

P921